About the Company
Genocea's mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS™ platform comprehensively profiles each patient's T cell responses to potential targets, or antigens, on the tumor. ATLAS enables us to optimize the neoantigens for inclusion in our immunotherapies and exclude inhibitory antigens, Inhibigens™, that can exert an immunosuppressive effect. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine and GEN-011, our neoantigen-specific cell therapy using T cells derived from peripheral blood.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $GNCA News
Axovant Shares Plummet On Alzheimer's Data; Genocea Gets Rocked -Biotech Movers
Meanwhile, shares of Genocea Biosciences Inc. closed at $1.25, down 76.6%, after the Cambridge, Mass.-based company on Monday announced a shift to immuno-oncology and a focus on developing ...
Genocea Biosciences Inc GNCAQ
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Genocea Biosciences – a Good Buy and Hold Stock
Here is one example currently running on my personal account. Recently, I bought 4,000 shares of Genocea Biosciences, Inc., (NASDAQ: GNCA). This company is listed in the Healthcare sector and ...
Lux Capital Management, LLC's Net Worth
This is based on reported shares across multiple companies, which include GENOCEA BIOSCIENCES, INC., Cerulean Pharma Inc., EVERSPIN TECHNOLOGIES INC, Kala Pharmaceuticals, Inc., and Science 37 ...
CRBU Caribou Biosciences, Inc.
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the ...
Plc Gsk's Net Worth
Plc Gsk has an estimated net worth of $9.11 Billion. This is based on reported shares across multiple companies, which include Wave Life Sciences Ltd., CVRx, Inc., Lyell Immunopharma, Inc ...
SPRB Spruce Biosciences, Inc.
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont ...
Cellectar Biosciences, Inc. (NASDAQ:CLRB): When Will It Breakeven?
We feel now is a pretty good time to analyse Cellectar Biosciences, Inc.'s (NASDAQ:CLRB) business as it appears the company may be on the cusp of a considerable accomplishment. Cellectar ...
Forte Biosciences Inc.
Forte Biosciences, Inc. is a biopharmaceutical company, which engages in the provision of dermatology products and services. The firm's lead product includes FB-401, which is a live biotherapeutic ...
Genocea Biosciences Inc GNCAQ
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Caribou Biosciences Inc (CRBU)
After-Hours Stock Movers: ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) 20% HIGHER; announced that it has expanded its current licensing agreement for trofinetide with Neuren ...
Genocea Biosciences, Inc. (GNCAQ)
Overall score is calculated based on proprietary scores based on sector averages in key company indicators: fair value, dividends, innovation, hiring, and insider sentiment. Note: if you don't see ...
Loading the latest forecasts...